1. Japan Stocks

  2. •

    Consumer non-durables

  3. •

    Household/Personal care
Kobayashi Pharmaceutical Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd.

40.40
EUR
0.00
(0.00%)
2.17BMarket Cap
Nov 10Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,483.98
1,554.32
1,574.62
1,686.9
1,989.35
2,119.1
2,019.23
1,925.64
1,987.23
2,155.78
2,287.03
2,227.63
2,229.99
- -
Basic EPS, GAAP
148.68
150.28
152.72
165.55
201.31
228.04
244.07
245.7
252.35
259.61
268.16
135.42
49.19
- -
Free Cash Flow per Basic Share
77.74
124.17
144.37
126.41
242.96
206.32
194.92
253.79
233.4
203.38
63.17
-206.93
155.79
- -
Dividend per Share
40.99
42.99
43.58
47.17
55.11
60.96
68.01
74
80.01
84.4
95.24
100.96
102.97
- -
Book Value per Share
1,402.62
1,550.15
1,714.1
1,766.99
1,948.27
2,102.46
2,208.93
2,335.91
2,516.2
2,603.46
2,755.17
2,871.53
2,838.34
2,820.7
Tangible Book Value per Share
1,340.44
1,483.9
1,645.56
1,700.59
1,887.49
2,041.46
2,169.12
2,172.23
2,353.37
2,428.4
2,464.42
2,593.42
2,604.09
2,597.45
Basic Weighted Avg Shares
82
82
82
81
79
79
78
78
78
77
76
74
74
74
Sales/Revenue/Turnover
121,532
127,293
128,344
137,211
156,761
167,479
158,340
150,514
155,252
166,258
173,455
165,600
165,742
- -
Operating Margin (%)
13.91
14.24
13.96
13.31
14.63
15.7
16.21
17.24
16.79
16.04
14.86
15.02
9.01
- -
Depreciation Expense
2,969
3,096
3,095
3,071
3,519
3,403
4,127
4,106
4,835
5,358
6,057
8,022
8,745
- -
Net Income, GAAP
12,176
12,307
12,448
13,466
15,863
18,023
19,139
19,205
19,715
20,022
20,338
10,067
3,656
- -
Effective Tax Rate (%)
35.41
37.42
37.93
28.26
29.72
28.77
28.6
27.9
28.66
28.36
26.2
27.61
2.22
- -
Profit Margin (%)
10.02
9.67
9.7
9.81
10.12
10.76
12.09
12.76
12.7
12.04
11.73
6.08
2.21
- -
Working Capital
59,876
71,398
80,100
83,866
88,072
96,771
109,279
114,118
131,186
121,083
102,220
98,045
88,683
86,757
LT Debt
163
609
513
618
527
472
682
505
460
531
608
503
359
452
Total Equity
114,870
126,951
139,609
142,023
153,810
166,247
172,657
182,582
195,599
197,899
204,816
213,470
211,008
209,697
Return on Invested Capital (%)
9.59
9
8.03
9.02
10.53
11.23
10.39
10.14
9.54
9.45
9.19
8.42
6.77
- -
Return on Capital (%)
11.18
10.14
9.3
9.54
10.68
11.21
11.24
10.77
10.4
10.15
10.07
4.8
1.73
- -
Return on Common Equity (%)
11.24
10.18
9.34
9.57
10.73
11.26
11.29
10.81
10.43
10.18
10.1
4.81
1.72
- -

Capital Structure

JPY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
319
- -
271
LT Borrowings
- -
- -
- -
LT Finance Leases
359
- -
452
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
74
74
74
Market Capitalization
390,667
430,893
403,156

Working Capital

JPY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
148,820
- -
124,828
Cash, Cash Equivalents & STI
70,614
- -
57,329
Accounts Receivable, Net
52,180
- -
34,125
Inventories
22,752
- -
29,937
Total Current Liabilities
60,137
- -
38,071
Payables & Accruals
- -
- -
- -
ST Debt
319
- -
271
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.26%
2.98%
-1.15%
Free Cash Flow
-60.56%
-137.57%
-175.27%
Net Income, GAAP
-6.22%
-21.68%
-63.68%
Sales/Revenue/Turnover
2.77%
2.03%
0.09%
Total Cash Common Dividend
8.03%
5.81%
1.97%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
36,485
36,651
41,323
51,141
165,600
2025
- -
- -
- -
- -
165,742
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13.13
6.19
52.57
63.53
135.42
2025
- -
- -
- -
- -
49.19
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
100.96
2025
- -
- -
- -
- -
102.97
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Norikazu Toyoda
Full Time Employees
3,731
Sector
Consumer non-durables
Industry
Household/Personal care
Address
KDX Kobayashi Doshomachi Building Osaka OS Japan 541-0045
IPO Date
Apr 20, 1999
Website
kobayashi.co.jp
Similar Companies
Procter & Gamble Company (The) (NYSE:PG)
Cupid Limited (NSE:CUPID)
Hindustan Unilever Limited (NSE:HINDUNILVR)
Colgate-Palmolive (India) Limited (NSE:COLPAL)
Dabur India Limited (NSE:DABUR)
e.l.f. Beauty, Inc. (NYSE:ELF)
Business
Kobayashi Pharmaceutical Co., Ltd. manufactures and sells over-the-counter pharmaceuticals, quasi-drugs, deodorizing air fresheners, sanitary products, cosmetics, health foods, and daily necessities in Japan and internationally; offers specific brands including Ammeltz anti-inflammatory pain relief medicine, Dent effervescent denture cleaning agent, Ekitai Bluelet Okudake toilet bowl cleaner, Naicitol Chinese medicine, BreathCare oral breath freshener capsules, Netsusama cooling gel sheets, lens cleaners, oral hygiene products, and body warmers; and provides synthetic resin processed products, nutritional supplements via mail order, skincare items, and paper products. The company operates through domestic and international business segments targeting consumer health, personal care, and household markets primarily in Asia with headquarters in Osaka, Japan, where it was founded in 1886. It also engages in transportation, real estate management, advertising production, and asset management activities. In recent developments, Kobayashi Pharmaceutical faced a major health crisis in 2024 involving its red yeast rice supplements linked to reported deaths, prompting a CEO replacement in July 2024 and ongoing activist investor pressure from Oasis Management, which acquired a 5.2% stake, filed a shareholder derivative lawsuit in April 2025, and submitted a shareholder proposal in December 2025 to enhance governance and operational efficiency.